Search

Your search keyword '"Zu, Youli"' showing total 643 results

Search Constraints

Start Over You searched for: Author "Zu, Youli" Remove constraint Author: "Zu, Youli"
643 results on '"Zu, Youli"'

Search Results

251. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma

255. Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma

256. Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning

257. MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup

258. DNA Aptamer Against Anti- Programmed Cell Death-1 (Anti-PD1-Apt) Induces Robust Anti-Leukemic Activity In Vitroand In VivoHumanized NSG Mice with Myeloid Leukemia Xenografts

259. Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia.

260. Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine.

261. Light Microscopic and Ultrastructural Evidence of in Vivo Phagocytosis of Helicobacter pyloriby Neutrophils.

262. STAT3 Expression and Clinical Implications In De NovoDiffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program

263. MYCMutation Profiling In 708 De NovoDiffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program

264. Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYCTranslocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program

265. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.

266. A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors.

267. Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells.

268. Aptamer Targets Triple-Negative Breast Cancer through Specific Binding to Surface CD49c.

269. Neutralizing Aptamers Block S/RBD‐ACE2 Interactions and Prevent Host Cell Infection.

270. G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?

271. High levels of immunoglobulin expression predict shorter overall survival in patients with acute myeloid leukemia.

272. Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein.

273. High‐Throughput Isolation of Cell Protrusions with Single‐Cell Precision for Profiling Subcellular Gene Expression.

274. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

275. Spin-Valve based magnetoresistive nanoparticle detector for applications in biosensing.

276. 18. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.

277. High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.

278. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program.

279. Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers.

280. Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.

281. Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex

282. Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system.

283. Unique biomechanical interactions between myeloma cells and bone marrow stroma cells

284. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition

285. Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells.

286. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions

287. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

288. Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.

289. Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS.

290. Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis.

291. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.

292. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy.

293. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.

294. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential.

295. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.

296. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.

297. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.

298. RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway.

300. Oligonucleotide aptamers for pathogen detection and infectious disease control.

Catalog

Books, media, physical & digital resources